IRF4 and B-cell non-Hodgkin lymphoma: The enriched pathways predominantly include those associated with ABC-type DLBCLs, B-cell lymphomas with plasmacytic differentiation, and activated B-/myeloma cells downstream of IRF4/MUM1 transcriptional activity [28,29].